Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Clinical Neurophysiologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
January 25, 2008
Artificial Cervical Disc Looks Promising
Analysis of: Artificial Disc Versus Fusion: A Prospective, Randomized Study With 2-Year Follow-up on 99 Patients | www.medscape.com
Author: GLG Expert Contributor
Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.
Daniel WynnJanuary 18, 2008
Major Win For Glaxo with Xenoport for Restless Legs syndrome -- Next Blockbuster?
Analysis of: GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262 | www.pipelinereview.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3  trial, should be a major win in the marketplace.  RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.
November 30, 2007
Lacosamide Should Solidify UCB as CNS Drug Leader
Analysis of: UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures | www.reuters.com
Author: GLG Expert Contributor
UCB has filed new drug application for regulatory approval for lacosamide through FDA and European Medicines Agency.  Primary indication would be the treatment of partial onset seizures (epilepsy)
August 22, 2007
Hydrocodone -- The Return of Hill Billy Heroin?
Analysis of: Painkiller Widely Abused in South | www.washingtonpost.com
Author: GLG Expert Contributor
The article describes the increase in hydrocodone abuse, especially in the Southern and Rural US.
August 21, 2007
Medical Tourism -- Bargain or Boondoggle?
Analysis of: American's Gamble for Bargain Surgery Abroad | www.medpagetoday.com
Author: GLG Expert Contributor
The article describes several examples of medical tourism with different motivations and risks involved.
August 17, 2007
Novel Experimental Approach to Gliomas
Analysis of: Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab | www.pipelinereview.com
Author: GLG Expert Contributor
The articel discusses Oncoscience AG, the european partner of YM BioSciences experimenal treatment for gliomas.  It is based on a monoclonal antibody to EGFR and is being tested in combination with other treatments including radiation.
August 16, 2007
New Myasthenia Treatment Makes Sense
Analysis of: New Treatment Boosts Muscle Function In Myasthenia Gravis | www.medicalnewstoday.com
Author: GLG Expert Contributor
The article reports on an open label study recently published in Neurology.  Apparently a new treatment (oral EN101 antisense) appears to be effective at improving muscle strength and reducing fatigue in people with MG. 
August 13, 2007
New MS treatments to be based on genetic breakthrough?
Analysis of: Genetic breakthrough offers MS sufferers hope of new treatment | www.timesonline.co.uk
Author: GLG Expert Contributor
Two genes have been linked to an increased risk for the development of MS.  Several researchers speculate on the ipact this may have on future treatments.
July 30, 2007
Branded drugs have value in epilepsy, but future is unclear
Analysis of: Industry Fights Switch to Generics for Epilepsy | online.wsj.com
Author: GLG Expert Contributor
The epilepsy foundation and major drug manufacturers have teamed up to protect reimbursments for branded anti-epilepsy drugs.
July 30, 2007
Branded drugs have value in epilepsy, but future is unclear
Analysis of: Industry Fights Switch to Generics for Epilepsy | online.wsj.com
Author: GLG Expert Contributor
The epilepsy foundation and major drug manufacturers have teamed up to protect reimbursments for branded anti-epilepsy drugs.

Previous Page : 1 2 3 4 5 Next11 to 20 of 46

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773